Astellas Signs Up Medivation Drug | November 2, 2009 Issue - Vol. 87 Issue 44 | Chemical & Engineering News
Volume 87 Issue 44 | p. 15 | Concentrates
Issue Date: November 2, 2009

Astellas Signs Up Medivation Drug

Department: Business
Keywords: drug development, urology, oncology

Astellas Pharma and Medivation have signed a deal to develop and co-commercialize MDV3100, a Medivation drug currently in Phase III trials for the treatment of prostate cancer. Under the agreement, San Francisco-based Medivation will receive an up-front cash payment of $100 million and milestone payments of up to $335 million. “We believe that MDV3100 has the unique potential to establish a new treatment approach for prostrate cancer,” Astellas CEO Masafumi Nogimori says.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment